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ABSTRACT
Treatment of patients with metastatic colorectal can-
cer has changed in recent years, with many patients 
now being offered intent-to-treat regimens. In this 
context, a multidisciplinary approach to the metastatic 
disease may lead to individualized treatment for any 
patient. Stereotactic body radiotherapy (s b r t ) is not 
the most common treatment. Here, we present the 
clinical case of a patient with a solitary liver metas-
tasis initially treated with s b r t  that was rescued with 
surgery when a local recurrence was detected.
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1.  INTRODUCTION
Nearly 150,000 americans are diagnosed with color-
ectal cancer (c r c ) annually, with one third dying from 
their disease, most from metastatic tumours 1. liver 
is the main metastatic site for patients with c r c , and 
although two thirds of affected patients experience ex-
trahepatic spread, in some cases the disease is isolated 
to the liver. For patients with isolated liver metastases, 
regional treatment approaches may be considered as 
an alternative to systemic chemotherapy.
The available regional treatments for hepatic 
metastases from c r c  include surgical resection, lo-
cal tumour ablation (that is, instillation of alcohol 
or acetic acid directly into the metastatic lesions), 
cryotherapy, radiofrequency ablation, regional hepatic 
intra-arterial chemotherapy or chemoembolization, 
and radiation therapy.
although hepatic resection was once reserved for 
patients with a maximum of three lesions in the same 
lobe (if achieving 1-cm margins was possible) and with-
out portal lymph node metastases, all of these “rules” 
have been challenged today, particularly with advances 
in surgical technique and more effective systemic   
therapies 2. as a result, there are no widely accepted 
criteria defining the patients that are best suited for sur-
gical therapy, and most clinicians take an aggressive 
stance in the management of hepatic metastases.
local tumour ablation can be accomplished 
with direct intratumoral instillation of alcohol 3 
or acetic acid 4 or with hyperthermic ablation 5 or 
cryotherapy 6. In general, lesions that are amenable 
to surgical resection also lend themselves to ablative 
treatments. Thus, local ablative methods may be con-
sidered a less morbid alternative to surgical resection 
in patients who are at high risk or are otherwise not 
candidates for surgery 7.
Since the late 1990s, technological advances 
in radiation planning [conformal radiation therapy, 
intensity-modulated radiation therapy, stereotactic 
body radiation therapy (s b r t )] and delivery (image-
guided radiation therapy, breathing motion manage-
ment strategies) have allowed high-dose external-
beam radiation therapy to be safely delivered focally 
to liver metastases, extending the role of radiation 
therapy to definitive therapy, with the potential for 
eradication of the disease and possibly cure in ap-
propriately selected patients. In addition, radiation 
therapy may play a role in the downstaging of border-
line resectable tumours after failure of chemotherapy 
to achieve this goal, when used in conjunction with 
other liver-directed therapies.
1.1  SBRT
The use of s b r t , which refers to a limited number 
of high-dose fractions delivered very conformally 
to extracranial targets using radiation doses higher 
than those used in standard fractionation, in the 
treatment of liver metastases is not common, but 
has been established 8–12. With s b r t , highly confor-
mal radiation therapy can be delivered in far fewer 77
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treatments than are possible with conventional 
radiation therapy. The shorter treatment times with 
s b r t  can overcome tumour repopulation, and the 
technique is therefore advantageous in terms of 
resource utilization and patient convenience. liver 
toxicity following s b r t  has seldom been observed, 
largely because most of the tumours being treated 
are small (predominantly less than 8 cm in their 
maximum dimension), usually requiring less than 
25% of residual liver to be irradiated.
Safety for s b r t  in 1–10 fractions has been de-
scribed in several retrospective series and more 
recently confirmed in prospective dose escalation 
studies. The Swedish group led by Blomgren 8 was 
the first to use s b r t  to treat liver metastases. In 1995, 
they reported a response rate of 43% for 14 liver me-
tastases treated with 20–45 Gy in 1–4 fractions, with 
a prolonged time to maximum response (approxi-
mately 16 months for a 13-cm liver metastasis). No 
liver toxicity was observed, but 1 patient developed 
grade 4 hemorrhagic gastritis. In a 1998 update 13, 
the local control rate was 95% with a mean survival 
of 17.8 months after s b r t  for 21 patients with liver 
metastases. In another series 14, 20 Gy in 2 fractions 
or 15 Gy in 3 fractions was used, with no serious 
toxicity in patients with recurrent liver metastases 
following resection. The subsequent local control 
ranged between 13 months and 101 months.
a group from Germany 9 used s b r t  in a 3-fraction 
trial. They recruited 51 patients with liver metastases; 
of these patients, 23 had c r c  liver metastases. These 
authors found reduced local control for c r c metastases 
as compared with metastases from other cancer types, 
as others have also observed. That finding may be a 
result of the rationale of treating c r c  liver metastases 
with ablation or surgery, which may in turn influence 
patient selection, so that patients referred for s b r t  are 
later in their natural history.
The maximum tolerated dose to liver using s b r t  
was not reached in a prospective study of 14–26 Gy in 
1 fraction in 60 liver tumours (56 metastases). Median 
tumour volume was 10 mL (range: 1–132 mL). Local 
control was 81% at 18 months 15. a North american 
prospective study of 18 patients with 25 tumours of 
no more than 6 cm demonstrated the feasibility of 
3 fractions of s b r t  up to 20 Gy 16.
a Canadian s b r t  study described the safety of 
delivering s b r t  in 6 fractions, using an individualized 
dose allocation in liver cancers ranging from 3 ml 
to 3000 ml 17. This phase i/ii study was conducted 
by dawson et al. at Princess Margaret Hospital in 
Toronto. Their work encompassed s b r t  with indi-
vidualization of immobilization, radiation planning, 
margin determination for the planning target volume, 
image guidance strategy, and prescription dose. 
Breath-hold was used to immobilize the liver when 
feasible. Image-guidance strategies included orthogo-
nal megavoltage images and orthogonal kilovoltage 
fluoroscopy using the diaphragm as a surrogate 
for the liver, and kilovoltage cone-beam computed 
tomography (c t ) using the liver or the tumour for 
guidance. The prescription dose was individualized to 
maintain the same estimated risk of radiation-induced 
liver disease, based on a normal-tissue complication 
probability model, with a maximum permitted dose 
of 60 Gy in 6 fractions.
1.2  Patient Selection for SBRT
Ideally, s b r t  should be used for patients with no more 
than 5 focal metastases less than 8 cm maximum in 
diameter (because local control is better for smaller 
tumours), not adjacent to the stomach or the small 
bowel, with a breathing motion of less than 5 mm. 
anatomically, patients with tumours distant from 
gallbladder, caudate lobe, and capsule are more suit-
able. More commonly, patients may have less liver 
volume, more breathing motion (up to 30 mm), and 
more lesions. As the tumour factors reduce the benefit 
of local control and as risk of toxicity increases, the 
rationale for radiation therapy is reduced.
The most challenging patients to treat are those 
with underlying liver disease such as cirrhosis or 
hepatitis (viral hepatitis must be treated before 
radiation is delivered), with less than 700 mL of 
uninvolved liver, with more than 5 metastases, and 
with a larger respiratory motion (>30 mm). Tumours 
close to the stomach and duodenum are the most 
challenging and difficult to cure, because stomach 
and duodenum tolerances are below the doses most 
likely to control liver metastases.
2.  CASE REPORT
a 67-year-old man with previous history of rectosig-
moid adenocarcinoma and rising serum carcinogenic 
embryonic antigen (c e a ), presented to our hospital for 
a second opinion.
This patient’s history revealed the diagnosis 
of rectosigmoid adenocarcinoma cT3N0M0 at an-
other centre in November 2004. He was treated with 
neoadjuvant chemoradiation therapy, receiving oral 
capecitabine 835 mg/m2 twice daily until January 
2005 and completing 50.4 Gy radiation therapy with 
good tolerance.
Surgery was performed in February 2005. The 
pathology from a low anterior resection confirmed 
a low-grade adenocarcinoma that had infiltrated the 
surrounding fat, with 3 positive lymph nodes from 
a total of 10 isolated.
The patient then received 6 cycles of adjuvant chem-
otherapy with capecitabine 1250 mg/m2 on days 1–14 
every 21 days, without any relevant toxicity.
In July 2005, c t  and magnetic resonance imaging 
of the liver resulted in a diagnosis of liver progression 
with a solitary liver metastasis to the viii segment and 
rising serum c e a  (to 34.5 ng/mL). The patient then 
began chemotherapy with f o l f o x 6–bevacizumab 78
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every 4 days for a total of 18 cycles. The response 
to this regimen was considered a partial response, 
and the patient was evaluated for surgical resection 
of the metastasis. However, because of the proxim-
ity of the vascular axis of the liver, he was deemed 
not amenable for resection and was recommended 
for s b r t .
In May 2006, he was treated with liver s b r t  in 4 
sessions, for a total of 36.5 Gy. a subsequent control 
positron-emission tomography (p e t) scan was nega-
tive, and the patient was considered to be in complete 
clinical response. He then continued chemotherapy 
with oral capecitabine 1250 mg/m2 on days 1–14 
every 21 days, until the visit to our clinic. Before this 
consultation, his serum c e a  had risen to 12 ng/ml 
from 4 ng/mL at the time of his first evaluation, and 
no change in the treatment plan had been discussed. 
a p e t–c t  was then requested.
The p e t–c t  (Figure 1) showed activity at the viii 
liver segment, with a standardized uptake value of 18.7 
for the same area in which the tumour had previously 
progressed and been treated with radiosurgery.
The case was discussed at our tumour board, and 
we decided to offer metastasis resection.
after a full colonoscopy, which revealed no le-
sions, the patient was operated on, and most of the 
lesion was resected (Figure 2). Examination of the 
abdominal cavity showed no abnormality, and some 
biopsies were taken.
a hepatic biopsy was submitted for diagno-
sis. Grossly, the specimen measured 6.5×5×3 cm 
(Figure 3). The capsule was smooth. At cut section, a 
well-delineated tumour mass measuring 2.5×2×2 cm, 
whitish and firm, was observed. Microscopically 
(Figure 4), the tumour consisted of large atypical 
glands, with a tubular and cribriform pattern of 
growth and garland dirty necrosis in the centre. The 
tumour cells exhibited nuclear pleomorphism. Fo-
cally, the interface of the tumour and the hepatic 
tissue showed heavy inflammatory infiltration with 
microvascular proliferation. The tumour infiltrated the 
adventitia of a large venule. The surrounding hepatic 
tissue showed macrovesicular steatosis and narrow-
ing of the small terminal hepatic veins with loose 
subintimal mesenchyme and fibrosis. The surgical 
margins were free of tumour.
No complication was recorded during the post-
operative period, and the patient was discharged on 
the third day following surgery.
f i g u r e  1  A metabolic lesion with a standardized uptake value of 
18.7 was found at the hepatic Viii segment.
f i g u r e  2  Resection of the liver lesion.
f i g u r e  3  Hepatic cut section of a well-delineated tumour mass 
measuring 2.5×2×2 cm, whitish and firm.79
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3.  DISCUSSION
The main potentially curative option for patients 
with an isolated liver c r c  metastasis is surgical re-
section. For appropriately selected patients with 4 
or fewer metastases, the 5-year relapse-free survival 
rate averages 30%; in at least four contemporary 
series, the 5-year overall survival rate is approxi-
mately 58% 18,19.
New techniques such as radiofrequency ablation 
or s b r t  may offer extended survival for selected pa-
tients and warrant the inclusion of s b r t  as part of an 
intent-to-treat strategy. Fewer than 20% of patients 
may experience local recurrence 8,20,21, and even if 
selection bias is believed to exist in the series data, 
the results of s b r t  remain impressive. Our case also 
reflects the role played by the new imaging techniques 
and the importance of c e a  in managing c r c .
4.  CONCLUSIONS
The case presented here is an example of the neces-
sity for managing metastatic c r c  in multidisciplinary 
groups in which all of the therapeutic options are dis-
cussed. Integration of radiotherapists into the multi-
disciplinary management of patients with metastatic 
c r c  is, in our opinion, mandatory.
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